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Abstract
Background: Japanese encephalitis virus (JEV), a member of the family Flaviviridae, is an important
mosquito-borne human pathogen. Its envelope glycoprotein (E) is the major determinant of the
pathogenicity and host immune responses. In the present study, we explored the feasibility of
producing recombinant JEV E protein in the virus-free Drosophila expression system.
Results: The coding sequence for the signal sequence of premembrane and E protein was cloned
into the Drosophila expression vector pAc5.1/V5-His. A Drosophila cell line S2 was cotransfected
with this construct as well as a plasmid providing hygromycin B resistance. A cell line expressing
the JEV E protein was selected by immunofluoresence, confocal microscopy, and western blot
analysis using three different monoclonal antibodies directed against JEV E protein. This cell line
was stable in the yield of JEV E protein during two months in vitro maintenance in the presence of
hygromycin B. The results showed that the recombinant E protein had an expected molecular
weight of about 50 kilodalton, was immunoreactive with all three monoclonal antibodies, and found
in both the cytoplasm and culture supernatant. Sucrose gradient ultracentrifugation analysis
revealed that the secreted E protein product was in a particulate form. It migrated to the sucrose
fraction with a density of 1.13 g/ml. Balb/c mice immunised with the sucrose fraction containing the
E protein particles developed specific antibodies. These data show that functioning JEV E protein
was expressed in the stable S2 cell line.
Conclusion: The Drosophila expression system is a more convenient, cheaper and safer approach
to the production of vaccine candidates and diagnostic reagents for JEV.
Background
Japanese encephalitis virus (JEV) is a member of the genus
Flavivirus in the family flaviviridae. It is the most common
agent of viral encephalitis, causing an estimated 50,000
cases annually, of which 15,000 will die and up to 50% of
survivors are left with severe neuropsychiatric sequelae
[1,2]. Most cases occur in southern and eastern Asia, but
the geographical area affected by JEV is expanding. Out-
breaks have been reported in Saipan islands, Torres Straits
islands and on Australia mainland in recent years [3-5].
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Cases have also occurred among travellers and US service-
men to Asia [6,7]. In addition, related neurotropic flaviv-
iruses are found across the globe; they share many
virological, epidemiological, and clinical features.
The flavivirus viron contains an envelope glycoprotein
(E), a membrane protein (M) and a capsid protein (C).
These three structural proteins are synthesized in the order
of C, M and E from the 5' half of a single long open read-
ing frame of the flavivirus genome. The M protein is found
in infected cells as a glycosylated precursor, called pre-
membrane protein (preM). The preM and E proteins
appear to be released from the nascent polyprotein fol-
lowing cotranslational cleavage by signal peptidases. Late
in viron maturation, preM is cleaved to M, presumably by
a cellular protease located in the secretary pathway, and M
appears to be the predominant species present in extracel-
lular virus particles although some uncleaved preM is also
present [8]. Flavivirus-infected cells release not only infec-
tious virons but also non-infectious subviral membrane
particles containing the M and E proteins but no C protein
or viral RNA, known as slowly sedimenting hemaggluti-
nin particles [9]. Similar particles can be produced using
various eukaryotic expression systems [10-16]. For JEV,
such particles were produced in mammalian cells infected
with recombinant poxviruses encoding the signal
sequence of preM, preM and E proteins, and were desig-
nated as the subviral extracellular particles (EPs). They are
membrane vesicles of 20 nm in diameter containing JEV
preM/M and E proteins embedded in the lipid bilayer,
and showed similar behaviour to the slowly sedimenting
hemagglutinin particles released from JEV-infected cells
on sucrose density gradients [10,17]. Mice immunised
with EPs were protected from lethal JEV infection [11]. In
addition, the JEV EPs were also found in plasmid-based
mammalian cell expression system. The recombinant
plasmid was tested as a DNA vaccine candidate against
JEV: it elicited immune response in mice [18,19]. Partially
purified JEV EPs were used as standard antigens for sero-
diagnosis of JEV infection [20]. JEV preM and E proteins
were expressed in Sf9 insect cells infected with recom-
binant baculovirus, and the intracellular E protein was
shown to be protective in mice against lethal JEV chal-
lenges [21,22]. It is not known whether EPs were formed
or not in this system.
Despite of the successful expression of flavivirus E pro-
teins and formation of subviral EPs in mammalian cells or
baculovirus-insect cell system, the disadvantages related
with these expression systems make it difficult to produce
and purify EPs in a large scale: the culture of mammalian
cells is expensive; virus-based expression is transient and
the maintenance or scale-up of virus stock requires a con-
siderable and dedicated effort; viral proteases and cell
lysate can cause degradation of the desired proteins and it
is difficult to separate desired EPs from the recombinant
virus particles.
To address these problems, the nonlytic, virus-free Dro-
sophila Expression System (DES) was employed in this
study as an alternative approach to produce JEV E protein
and EPs to be used as a vaccine candidate and diagnostic
reagent. The DES utilises a cell line derived from Dro-
sophila melanogaster, Schneider 2 (S2) cells, the genome of
which has been completely sequenced [23], and a simple
plasmid vector for the expression of heterologous proteins
using either the metallthionein (MT) promoter [24,25] or
the Actin 5C (Ac5) promoter [26]. S2 cells are easily main-
tained in loosely adherent or suspension culture at room
temperature and do not require CO2. Many foreign signal
sequences are functional in S2 cells and can be used to
secrete proteins. This system has been used to produce
many foreign proteins, including viral antigens [27,28]. In
the current report, we described establishment of a stable
S2 cell line producing JEV subviral EPs containing E pro-
tein and the characterisation of their antigenicity and
immunogenicity.
Results
Sequence validation of recombinant expression vectors
The inserts of pAc/ZF-ZR and pAc/JEF-JER were
sequenced. In comparison to pJEV1, the recombinant cos-
mid clone containing JEV cDNA and used as the template
DNA (our unpublished data), no sequence differences
were found. The cloning sites of all four constructs were
confirmed to be the context as designed.
Expression of JEV E protein in S2/ZF-ZR and S2/JEF-JER 
cells
Transfected S2 cells, either S2/ZF-ZR or S2/JEF-JER
appeared normal morphologically and their growth was
comparable with normal control S2 cells. Indirect
immunofluorescence with monoclonal antibody (MAb)
2H4, 2F2 or mc3 revealed that the recombinant JEV E pro-
tein expressed in either cell line was accumulated in vesi-
cle-like structures in the cytoplasma, and there was no cell
surface staining (Fig. 1). This was confirmed by confocal
microscopy (data not shown). There was no difference in
staining patterns among these three antibodies. The
recombinant JEV E protein expressed in S2/ZF-ZR, S2/JEF-
JER or Vero cells transfected with pVAX/ZF-ZR or pVAX/
JEF-JER was analysed by Western blot with antibody 2F2.
They all had the same molecular weight of about 50 kDa
as expected (Fig. 2).
To determine the effect of preM signal sequence on the
secretion of E protein from transfected S2 cells, cell lysate
and culture supernatant of S2/ZF-ZR or S2/JEF-JER, which
has a 19-peptide or 9-peptide preM signal sequence
respectively, were analysed by Western blot. The samplesVirology Journal 2007, 4:17 http://www.virologyj.com/content/4/1/17
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were standardised according to the cell number or culture
density. S2/ZF-ZR and S2/JEF-JER had the similar expres-
sion level of intracellular form of E protein, while the
extracellular E protein was only detected from the former
culture supernatant by the Western blot (Fig. 3). Results
show that all three MAb 2F2, 2H4 and mc3 were directed
against conformational epitopes and disulfide bond
dependent. They were reactive with the recombinant E
protein expressed in either S2 or Vero cells only if the sam-
ples were prepared in the absence of the reducing agent
such as β-mercaptoethanol or dithiothreitol.
Characterisation of extracellular-form of JEV E protein 
expressed in S2/ZF-ZR cells
The culture medium harvested from S2/ZF-ZR cells was
centrifuged through a 10% (W/V) sucrose cushion, and
Western blotting was used to determine the distribution
of the extracellular E protein in the pellet, cushion or cul-
ture supernatant. The results demonstrated that about
90% of the extracellular E protein was sedimented
Comparison of recombinant JEV E protein expressed in def- erent cells by Western blot Figure 2
Comparison of recombinant JEV E protein expressed 
in deferent cells by Western blot. Cell lysate were 
resolved by 12% SDS-PAGE under non-reducing conditions. 
After electrophoresis proteins were transferred onto nitro-
cellulose membrane and probed with the antibody 2F2. ECL 
reagents were used to visualise protein bands. Lanes 1 to 6 
are the cell lysate from Vero/ZF-ZR, Vero/JEF-JER, S2/ZF-
ZR, S2/JEF-JER, Vero and S2 cells respectively.
Immunofluorescence analysis of S2/ZF-ZR and S2/JEF-JER cells with antibody 2F2 Figure 1
Immunofluorescence analysis of S2/ZF-ZR and S2/JEF-JER cells with antibody 2F2. S2 cells were transfected with 
pAc/ZF-ZR (frame A) or pAc/JEF-JER (frame B). Transfected cells were harvested in PBS and plated onto microscopic slides. 
After air drying, the cells were fixed in 10% formalin with 1% Triton X-100 at room temperature for 30 min. The cells were 
incubated subsequently with JEV E specific monoclonal antibody 2F2 and a fluorescein-conjugated secondary antibody (DAKO) 
at room temperature for 1 hr. Each incubation was followed by two washes in PBS. Finally the slides were mounted with 
VECTASHIELD Mounting Medium containing propidium iodide (Vector Laboratories) and viewed under an Olympus fluores-
cence microscope. The green fluorescence indicates the detection of JEV E proteins.Virology Journal 2007, 4:17 http://www.virologyj.com/content/4/1/17
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through the sucrose cushion (data not shown). The pellet
was resuspended and was further resolved by centrifuga-
tion through the 10–60% (W/V) sucrose gradient. Twelve
fractions of 1 ml were collected from the top to bottom
and analysed by Western blotting with antibody 2F2. The
E protein was mainly found in fraction 7 and 8, which had
an average density of 1.13 g/ml, but also detectable in oth-
ers (Fig. 4). The Coomassie blue stained SDS-PAGE gel
showed that E protein was the main protein component
in fraction 7 and 8, and the average concentration of E
protein in fraction 7 and 8 was estimated at 2 µg/ml by
comparison with serial diluted bovine serum albumin
(data not shown). To determine whether or not the extra-
cellular form of E protein was associated with membrane
vesicles, the sucrose gradient fraction containing the peak
E protein (fraction 7) was diluted in PBS and treated with
Triton X-100 at a final concentration of 1 mg/ml. Samples
were applied again to the sucrose density gradient centrif-
ugation as described in the Materials and Methods. As
shown in Figure 5, following Triton X-100 treatment, the
peak of E protein shifted upward in the gradient, becom-
ing less dense. In contrast, the peak in mock-treated sam-
ples remained unchanged. These results indicate that
most of the E protein in the culture medium was in a form
of extracellular particles, in which the E protein was asso-
ciated with membrane vesicles.
Stability of the S2/ZF-ZR cell line
During a period of two months of in vitro maintenance in
the presence of Hygromycin B, no morphological change
was observed in the S2/ZF-ZR cell line. Cells were sampled
and extracted at an interval of 2 weeks as described in the
Methods and tested for JEV E protein by using Western
blotting. All 5 samples had a similar expression level of
JEV E protein as indicated by the Western blot band inten-
sity (data not shown).
Immune response in mice immunised with S2/ZF-ZR lysate 
and EPs
Balb/c mice (4 animal each group) were immunised with
S2/ZF-ZR EPs, lysate or PBS buffer (mock) respectively to
test the immunogenicity. Two weeks after second immu-
nisation (boost), mouse sera were collected and tested for
specific antibodies to JEV E protein by Western blot using
the Vero/ZF-ZR cell lysate as the antigen. Serum samples
diluted at 1:20 from 3 of 4 mice immunised with EPs were
positive for JEV E specific antibodies, whereas all the mice
inoculated with cell lysate or PBS were negative at a dilu-
tion of 1:10.
Discussion
The signal-preM-E cassette of JEV genome has been well
explored in both recombinant subunit vaccine and DNA
vaccine studies. This is based on the fact that the E protein
mediates receptor binding and membrane fusion and
induces protective immunity [29], the maturation of JEV
E protein requires cosynthesis of the preM protein [30]
and the signal sequence of preM signal affects the secre-
tion of the coexpressed E protein [17]. In the vaccinia-
mammalian cell system, preM/M and E gene in this cas-
sette were translated and processed correctly in terms of
molecular mass, glycosylation and antigenicity compared
to their natural counterparts. More importantly, the preM
and E proteins expressed by recombinant vaccinia viruses
could form slowly sedimenting hemagglutinin particle-
Distribution of JEV E protein in the sucrose gradient after  ultracentrifugation Figure 4
Distribution of JEV E protein in the sucrose gradient 
after ultracentrifugation. A, Western blot analysis of JEV 
E protein in the sucrose gradient fractions. B, density plot of 
the fractions and percentage distribution of JEV E proteins 
cross the fractions estimated by densitometry.
Effect of preM signal sequence on the secretion of E protein  from transfected S2 cells Figure 3
Effect of preM signal sequence on the secretion of E 
protein from transfected S2 cells. Cell lysate or culture 
supernatant was resolved by 12% SDS-PAGE under non-
reducing conditions. After electrophoresis proteins were 
transferred onto nitrocellulose membrane and probed with 
the antibody 2F2. ECL reagents were used to visualise pro-
tein bands. Lanes 1 to 4 are S2/ZF-ZR cell lysate, S2/ZF-ZR 
culture medium, S2/JEF-JER culture medium and S2/JEF-JER 
cell lysate respectively.Virology Journal 2007, 4:17 http://www.virologyj.com/content/4/1/17
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like EPs, in which the conformation of E protein was sim-
ilar to that in natural virons. Due to their good antigenic-
ity and immunogenicity, such EPs may be very useful in
both serological diagnosis and vaccination [11,20,31]. In
addition to mammalian expression system, structural pro-
teins of JEV and other flavivirus were also produced in
recombinant baculovirus-infected insect cells and trans-
formed yeast cells. Though intracellular-form of virus-like
particles or E protein aggregates was observed [16,32],
they failed to secrete in these systems. In the present study,
for the first time the above JEV cassette was expressed in
the plasmid-based, nonviral, nonlytic Drosophila Expres-
sion System.
The coding sequence of signal-preM-E cassette used in this
study was PCR-amplified from a full-length cDNA cosmid
clone of JEV SA14 strain, pJEV-1. A polymerase with
proof-reading activity was used in all PCR reactions to
ensure faithful amplification. The sequencing data
showed that pAc/ZF-ZR, pAc/JEF-JER and pJEV-1 had the
identical sequence in the signal-preM-E region, though six
differences were found when it was compared with the
published sequence. It appeared that these differences had
no adverse effect on the expression and antigenecity of E
proteins in either S2 or Vero cells: the E protein was
cleaved to the expected size and reactive with all three E
protein specific MAbs, 2F2, 2H4 and mc3. All these three
MAbs are neutralising in vitro and protective in vivo, and
have been approved for phase-I and II clinical trials as a
specific treatment agent for JEV infection in China. It is
encouraging to find that the recombinant E protein pro-
duced in either S2 cells or Vero cells lost its reactivity with
these MAbs in the presence of reducing reagents. This
indicated that the E protein expressed in S2 cells was cor-
rectly folded to present authentic epitopes. These findings
may explain previous observations that E protein pro-
duced in E. coli [33] and the authentic E protein prepared
in denaturing conditions [34] failed to induce neutralis-
ing antibodies.
The E protein expressed in S2/ZF-ZR cells were found
accumulated within vesicle-like structures in the cyto-
plasm, and also secreted into the culture supernatant.
Interestingly, the secretion of E protein in S2/JEF-JER cells,
which express shorter preM signal, preM and E, was dra-
matically reduced. This was consistent with the observa-
tion made with recombinant vaccinia viruses encoding
the similar cassettes from other flaviviruses, that longer
preM signal sequences led to higher secretion level of E
proteins [17]. It was proved in the current study that the
JEV preM signal peptide was recognized by Drosophila S2
cells and played an important role in the transportation
and secretion of the E protein.
The E protein in the culture supernatant of S2/ZF-ZR was
in a particulate form as shown in the sucrose density gra-
dient centrifugation. The Triton X-100 treatment experi-
ment further suggests that these particles were membrane
Effect of TX100 on the EPs containing JEV E protein Figure 5
Effect of TX100 on the EPs containing JEV E protein. Sucrose centrifugation-purified extracellular particles were 
treated with Triton X-100 (final concentration of 1 mg/ml), and then applied again to a 10–60% continuous sucrose gradient 
(W/V) centrifugation. Fractions were collected and analysed by Western blot. A, Triton X-100 treated sample; B, mock treated 
sample.Virology Journal 2007, 4:17 http://www.virologyj.com/content/4/1/17
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vesicles with the entrapped antigens. We have not con-
firmed immunologically the presence of preM/M protein
in the particles due to lack of appropriate antibodies.
There have been no reports on the buoyant density of JEV
EPs produced in mammalian cells [10,11]. In this study,
S2/ZF-ZR-produced EPs migrated to the fraction with an
average sucrose concentration of 34% (W/W) and a den-
sity of 1.13 g/ml, which are very close to that of other fla-
vivirus-like particles expressed in mammalian cells [16] or
yeast cells [32]. In agreement with the observation made
with JEV EPs produced in the mammalian cells [11], the
EPs produced by S2/ZF-ZR cells showed a much stronger
immunogenicity in mice than the intracellular form of E
protein within the cell lysate.
Another important feature of the S2/ZF-ZR cell line is its
stability in the constitutive expression of JEV E protein.
The yield of E protein remained at a similar level during
two months of in vitro maintenance in the presence of
Hygromycin B, indicating that the genotype of this cell
line is stable and S2 cells can tolerate JEV E protein.
Conclusion
JEV subviral extracellular particles containing functional E
protein were expressed constitutively in a stable S2 cell
line. Drosophila expression system is more convenient,
cheaper and safer approach to the expression of proteins
of interest, and may represent a promising alternative in
the production of vaccine candidates and diagnostic rea-
gents for JEV or other flaviviruses.
Methods
Construction of recombinant expression vectors
The coding sequence for 19-peptide preM signal peptide,
preM and E proteins was amplified by PCR from a cosmid
pJEV-1 containing the full-length cDNA of JEV SA14 [35].
The sense primer ZF, 5'-GC GAA TTC ATG GAA GGC TCA
ATC CAT GTG G-3', was engineered with an Eco RI site (in
bold) and a start codon (in italics) prior to the nucleotides
(nt) 420–439 in the JEV genome. The antisense primer
ZR, at nt position 2460–2478, 5'-GC CTCGAG CTA AGC
ATG CAC ATT GGT CGC-3', has an engineered Xho I (in
bold) and a stop codon (in italics). For comparison, the
coding sequence for a shorter preM signal peptide (9-pep-
tide), preM and E proteins was amplified with the primer
pair JEF/JER (5'-C GGTACC ATG GCA GTT GTC TAG CTT
GTG C-3'/5'- C G AATTC AGC ATG CAC ATT GGT CGC
TAA G-3'). The PCR product should contain an engi-
neered Kpn I site and start codon at the 5' end prior to nt
450, and an Eco RI site at the 3' end but no stop codon.
The Expand Long Template PCR system (Roche) was
employed in PCR amplification according to manufac-
turer's instructions. The PCR product primed by ZF/ZR
were double digested with Eco RI/Xho I, purified with the
Qiagen Gel Purification Kit (Qiagen) and ligated with the
linearised DES constitutive expression vector pAc5.1/V5-
His A or the mammalian expression vector pVAX1 (Invit-
rogen). The recombinant expression vectors were desig-
nated as pAc/ZF-ZR and pVAX/ZF-ZR respectively. The
PCR product primed by JEF/JER was double digested with
Kpn I/Eco RI, and ligated to appropriately linearised vec-
tor pAc5.1/V5-His A or pVAX1 to generate the recom-
binant plasmid, pAc/JEF-JER or pVAX/JEF-JER. The
cloning sites and full-length inserts of these four recom-
binant plasmids were sequenced. Plasmid DNA was pre-
pared using Qiagen Midiprep Kit (Qiagen).
Sequence Analysis
DNA sequencing and data analysis were performed as pre-
viously described [36].
Cell lines and antibodies
S2 cells were cultured in the DES Expression Medium
(Invitrogen) supplemented with 10% heat-inactivated
fetal bovine serum (Life Technologies) at room tempera-
ture without CO2. The DES Serum-Free Medium (Invitro-
gen) was used for expression and purification of secreted
proteins. Vero cells were cultured in DMEM medium (Life
Technologies) supplemented with 10% FBS and were
incubated at 37°C in an atmosphere containing 5% CO2.
Three monoclonal antibodies (MAbs) against JEV E pro-
tein, mc3, 2H4 and 2F2 were used in the detection of
expressed E protein [37].
Transfection of pAc/ZF-ZR or pAc/JEF-JER into S2 cells
The calcium phosphate coprecipitation method was used
to produce stable transformants. The transfection of S2
cells cultured in a 35 mm dish was carried out with 20 µg
of pAc/ZF-ZR or pAc/JEF-JER and 1 µg of pCoHYGRO
(Invitrogen), a plasmid carrying the hygromycin B-resist-
ance gene. The calcium phosphate-DNA precipitate was
incubated with the cells for 16–24 hr. The cells were then
washed twice gently with complete DES Expression
Medium, resuspended in 3 ml of DES Expression Medium
and replated into the original dish. After 2 days of further
incubation, the cells were centrifuged and resuspended in
complete medium containing hygromycin B (Invitrogen)
at a concentration of 300 µg/ml. The selective medium
was replaced every 4–5 days until resistant cells started
growing out in about 3 weeks. These cells were designated
as S2/ZF-ZR and S2/JEF-JER respectively.
Transient transfection of Vero cells with pVAX/ZF-ZR or 
pVAX/JEF-JER
The monolayer of Vero cells in a 35 mm plate was trans-
fected with 5 µg of pVAX/ZF-ZR or pVAX/JEF-JER in the
presence of Lipofectamine (Life Technologies) according
to the manufacturer's instruction. In parallel, the transfec-
tion was also carried out on 8-well chamber slides (Nunc).Virology Journal 2007, 4:17 http://www.virologyj.com/content/4/1/17
Page 7 of 8
(page number not for citation purposes)
Immunofluorescence analysis
Transfected or non-transfected S2 cells were pelleted,
resuspended in PBS and plated onto microscopic slides.
After air drying, the cells were fixed in 10% formalin with
1% Triton X-100 at room temperature for 30 min. Trans-
fected Vero cells grown on chamber slides were washed
with PBS and fixed similarly. The cells were washed and
incubated with a JEV E specific monoclonal antibody, and
then with a fluorescein-conjugated secondary antibody
(DAKO) at room temperature for 1 hr. Each incubation
was followed by two washes in PBS. Finally the slides were
mounted with VECTASHIELD Mounting Medium con-
taining propidium iodide (Vector Laboratories) and
viewed under an Olympus fluorescence microscope.
Transfected S2 cells were further examined under a confo-
cal microscope (Leiz).
SDS-PAGE and Western blot analysis
Transfected S2 or Vero cells were lysed at 37°C for 15 min
in the lysis buffer (50 mM Tris, pH 7.8, 150 mM NaCl, 1%
Nonidet P-40) supplemented with protease inhibitor
cocktail tablets (Roche). After centrifugation at 13,000
rpm for 15 min, the supernatant was recovered and stored
at -20°C. For SDS-PAGE, the cell lysate or culture medium
was mixed with 4 × sample buffer with or without β-mer-
captoethanol, and boiled for 5 min. After electrophoresis
on a 12% gel, protein bands were stained with Quick Blue
or Silver Stain (Sigma). Proteins were also transferred to
nitrocellulose membranes, probed with JEV E specific
antibodies and visualized by ECL reagents (Amersham).
Sucrose density gradient centrifugation analysis
S2/ZF-ZR cells (about 1 × 107) maintained in complete
DES Expression Medium with 300 µg of hygromycin B
were pelleted to remove the selective medium. They were
cultured for further 2 days in 10 ml of DES Serum-Free
Medium before the medium was collected and clarified by
centrifugation at 3,000 rpm. The clarified medium was
then centrifuged for 15 hr at 25,000 rpm in a Sorvall
TH641 rotor at 4°C onto a 10% sucrose cushion (W/V,
prepared with PBS). The pellet was resuspended in 1 ml of
PBS and applied to a 10–60% continuous sucrose gradi-
ent (W/V, prepared with PBS on BioComp automatic gra-
dient former) and centrifuged for 12 hr at 36,000 rpm in
a Sorvall TH641 rotor at 4°C. Fractions were collected by
upward displacement with MAXIDENS (Lipotek). The
sucrose density in the gradient fractions was determined
with a handheld refractometer (Bellingam + Stanley Lim-
ited). All fractions were analysed by Western blotting with
JEV E specific antibodies.
Treatment with Triton X-100 (TX100)
Sucrose centrifugation-purified extracellular particles
were diluted in PBS in the presence or absence of TX100
(final concentration of 1 mg/ml), and then applied to a
10–60% continuous sucrose gradient (W/V) prepared
with or without 1 mg/ml TX100. Both gradients were cen-
trifuged for 3 hr at 35,000 rpm in a Sorvall TH641 rotor at
4°C, and fractions were examined for JEV E antigenic reac-
tivity by Western blotting.
Animal experiments
Four-week-old female Balb/c mice were randomly
grouped (4 animals per group) and immunized with PBS,
S2/ZF-ZR lysate or extracellular particles containing E pro-
tein purified from the culture medium by sucrose density
gradient centrifugation. Each mouse received about 10 µg
E protein from cell lysate or 1 µg from sucrose fractions by
both subcutaneous (s.c.) and intraperitoneal injection
and (i.p.). For s.c. inoculation, the immunogen was emul-
sified with Freund's complete adjuvant, while no adjuvant
was used for the i.p. route. All the mice were boosted with
the same dose two weeks later. Blood samples were taken
from tails two weeks after the boost and tested for JEV spe-
cific antibodies by Western blot. The investigation con-
forms to the Animals (Scientific Procedures) Act 1986, UK
(Home Office Reference: PIL 70/16040). The cell lysate of
pVAX/ZF-ZR-transfected Vero cells was used as the anti-
gen.
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